The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: A systematic review and meta-analysis

Ítems similars

• Asymptomatic “breakthrough” thrombosis and anticoagulant “failure”: Keep calm and carry on
  per: Olson, Sven R., et al.
  Publicat: (2019)
• The safety and efficacy of novel agents targeting factor XI and XII in early phase human trials.
  per: DeLoughery, Emma, et al.
  Publicat: (2019)
• Direct Oral Anticoagulant (DOAC) versus Low-Molecular-Weight Heparin (LMWH) for Treatment of Cancer Associated Thrombosis (CAT): A Systematic Review and Meta-Analysis
  per: Li, Ang, et al.
  Publicat: (2018)
• Safety and efficacy of direct oral anticoagulants (DOACs) vs low molecular weight heparin (LMWH) in malignancy induced venous thromboembolism-a systematic review and meta analysis
  per: Abdul Razzack, A, et al.
  Publicat: (2021)
• The safety and efficacy of NOACs versus LMWH for thromboprophylaxis after THA or TKA: A systemic review and meta-analysis
  per: Kai Ding, et al.
  Publicat: (2024-10-01)